| |
LIFELINE BIOTECHNOLOGIES BEGINS MULTI-CENTER STUDY FOR ITS BREAST CANCER
>DETECTION PRODUCT, FIRST WARNING™
>
>Reno, Nevada—October 26, 1998—Lifeline BioTechnologies, Inc., (OTC BB:LBTI)
>has just received approval and verification of its clinical protocol to
>study 1200 women with the First Warning™ system.
>
>The study will be directed by Dr. Martin Laguens, who is a qualified medical
>investigator and is a board certified Anatomopathologist as well as
>Dermatopathologist. Dr. Laguens has conducted several studies for American
>medical companies. He will direct Lifeline's mutli-center study in Buenos
>Aires and La Plata, Argentina.
>
>The company chose this area because of the large number of unscreened female
>patients available for study through government medical programs as well as
>the high quality of Argentina's medical delivery system.
>
>The protocol is divided into three parts. One study group will be women
>referred to the breast clinic for clinical study because of existing
>problems. A second group will be women recommended for surgical biopsy.
>The third group will be women who have never been screened for breast
>cancer.
>
>The study start date is expected near term.
>
>Lifeline BioTechnologies, Inc.'s (Lifeline) has developed a non-invasive
>test for early breast cancer detection. The test is incorporated into a
>proprietary product called First Warning ™. In preliminary pilot studies,
>First Warning ™ demonstrated great promise in detecting formation of
>extremely early stage breast lesions, particularly in younger women.
>Management believes the product is an alternative to other breast cancer
>detection products, including technology from Trex Medical Corporation
>(Amex: TXM) and Computerized Thermal Imaging, Inc. (OTC BB:COII).
>
> The second product division under Lifeline BioTechnologies is a line of
>nutritional food supplements packaged and sold under the tradename NATURE'S
>CREATIONS. These supplements are marketed and directed towards people
>afflicted with degenerative diseases that are commonly found in the aging
>population. These diseases include cancer (breast, colon and prostate)
>cardiovascular, osteoporosis and mental alertness.
>
>For more information on Lifeline BioTechnologies, please visit,
>www.lbti.com.
>
>Financial Statements in this press release (if any) other than historical
>facts are "forward-looking" statements with the meaning of section 27A of
>the Securities Act of 1933, section 21E of the Securities Exchange Act of
>1934, and as that term is defined in the Private Securities Litigation
>Reform Act of 1995. The Company intends that such statements about the
>Company's future expectations, including future revenues and earnings, and
>all other forward-looking statements be subject to the safe harbors created
>thereby. Since these statements (future operational results and sales)
>involve risks and uncertainties and are subject to change at any time, the
>Company's actual results could differ materially from expected results.
>
>Contact:
>M&A West, Inc. (Investor Relations)
>Scott Kelly
>650-588-2678
>www.mawest.com |
|
